Sign in

CIK 0000921299

  • Non-accelerated filer
  • Smaller reporting company

KYNTRA BIO, INC.

Sign in to watch
Ticker
KYNB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
770357827
Phone
+1 415-978-1200
Business address
350 BAY STREET, SUITE 100 #6009, SAN FRANCISCO, CA, 94133
Former names
FIBROGEN INC
  1. 4 Open-market sale Director sold 6,000 shares at an average $42.60 ($255,570)
  2. 4 Open-market sale SVP, Clinical Dev, Drug Safety sold 2,873 shares at $45.00 ($129,285)
  3. 4 Open-market sale Chief Executive Officer sold 39,636 shares at an average $44.20 ($1,752,006)
  4. 4 Exercise or conversion SVP, Clinical Dev, Drug Safety acquired 16,000 shares (option exercise)
  5. 4 Open-market sale SVP, Finance and CFO sold 3,201 shares at $43.12 ($138,027)
  6. 4 Open-market sale SVP, China Operations sold 11,250 shares at an average $44.05 ($495,563)
  7. 4 Open-market sale Chief Medical Officer sold 3,420 shares at $40.96 ($140,083)
  8. 4 Grant or award Director acquired 4,648 shares (grant or award)
  9. 3 Insider Initial Statement of Ownership
  10. 4 Shares withheld for taxes Chief Medical Officer gave up 3,360 shares (to pay taxes)
  11. 4 Open-market sale Chief Executive Officer sold 39,636 shares at an average $38.21 ($1,514,452)
  12. 4 Shares withheld for taxes SVP, Clinical Dev, Drug Safety gave up 2,058 shares (to pay taxes)
  13. 4 Shares withheld for taxes SVP, Finance and CFO gave up 3,144 shares (to pay taxes)
  14. 4 Shares withheld for taxes SVP, China Operations gave up 3,480 shares (to pay taxes)
  15. 4 Grant or award Director acquired 4,700 shares (grant or award)
  16. 4 Insider Changes in Ownership
  17. 4 Insider Changes in Ownership
  18. 4 Insider Changes in Ownership
  19. 4 Insider Changes in Ownership
  20. 4 Insider Changes in Ownership

Page 16 of 38 · 760 filings